This article is more than 5 years old. Information may no longer be current.

Insulet, Eli Lilly join for OmniPod delivery of U200 concentrated insulin

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Insulet Corporation recently announced a development agreement with Eli Lilly to develop a version of the OmniPod tubeless insulin delivery system designed to delivery Lilly’s Humalog 200 units/mL insulin, according to a company press release.

The agreement will enable the companies to develop the first insulin pump specifically designed for delivery of the Humalog U200 insulin. The new system would help patients improve glycemic control without the use of multiple daily injections.

“We are thrilled to partner with Lilly to develop the first insulin pump specifically designed for Humalog U200 insulin,” Patrick Sullivan, CEO of Insulet Corporation, said in the release. “This partnership allows Insulet to deliver the advantages of our OmniPod System to individuals worldwide with higher insulin requirements so they can better control their diabetes. Using Humalog U200 in OmniPod’s tubeless design effectively doubles the number of insulin units available to users in a single pod. This will provide the freedom and ease of use of our OmniPod System to a broader range of individuals living with diabetes.”